SightGlass Vision Releases First White Paper on Diffusion Optics Technology

SightGlass Vision announced the release of its first white paper regarding the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering elements called dots, designed to mimic more natural contrast on the retina—a unique mechanism of action designed to slow myopia progression in children.

The paper explains the relationship between artificially high contrast signals at the retina and myopia progression. This research led to the development of DOT to manage such contrast, now clinically proven via the CYPRESS study to slow myopia progression in children from age 6. Its efficacy is particularly of note for the youngest patients, who would typically experience the fastest progression, according to SightGlass. 

The white paper can be read online or downloaded as a PDF at https://www.sightglassvision.com/resources-for-eye-care-professionals

“As a more recent entrant into the myopia management field, our Diffusion Optics Technology paper will help disseminate the substantial science behind contrast management and its application. DOT spectacle lenses present a compelling alternative to existing solutions for slowing myopia’s progression in children,” Andrew Sedgwick, SightGlass Vision’s CEO, said in a company news release.

Over the last 2 years, SightGlass Vision’s patent-protected technology made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.